Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on June 7, 2017, reporting events occurring on June 5 and June 6, 2017. The filing details a registered direct offering of common stock and warrants to institutional investors. Note: While the request metadata mentions "Opus Genetics, Inc.", the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $10 million from the sale of 3,030,304 shares of common stock and warrants exercisable for up to 1,515,152 shares.
- Offering Price: $3.30 per unit (one share plus a warrant for 0.5 shares).
- Net Proceeds: Approximately $9.3 million after deducting fees and expenses.
- Placement Agent Fees: Up to 6% of gross proceeds plus $30,000 in expenses paid to Rodman & Renshaw (Wainwright).
- Warrant Terms: Exercise price of $4.00 per share for investor warrants; $4.125 per share for agent warrants. Exercisable after six months, expiring five years later.
- Agent Warrants: Approximately 181,818 warrants issued to the placement agent (6% of shares sold).
Material Changes
The filing reports the entry into a Material Definitive Agreement (Item 1.01). There are no comparative financial metrics (revenue, profit, cash flow) provided in this specific filing as it is a current report regarding a capital raise rather than a periodic financial statement. The primary material change is the anticipated increase in cash liquidity and the dilution of existing shareholders due to the issuance of new shares and warrants.
Outlook, Risks, and Unusual Items
- Closing Date: The offering is expected to close on or about June 12, 2017, subject to customary conditions.
- Use of Proceeds: The filing does not specify the intended use of the net proceeds.
- Risks: The transaction involves the issuance of warrants with an exercise price ($4.00) higher than the offering price ($3.30), which may impact future dilution if exercised. The filing includes standard disclaimers that the agreements are not intended as factual disclosures for the public.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected June 12, 2017) and confirmation of fund receipt.
- Review the effective shelf registration statement (File No. 333-196255) for the full prospectus supplement.
- Confirm the exact number of shares issued and the final net proceeds after all expenses.
- Assess the impact of the new share issuance and warrant overhang on existing shareholder equity.
- Check subsequent filings for the specific allocation of the $9.3 million in net proceeds.